

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A mouse model of Guillain-Barré syndrome ~~which can be obtained by immunizing with gangliosides GQ1b a homozygous FcγRIIB gene deficient mouse whose FcγRIIB gene function is deficient in its chromosome with GQ1b ganglioside to develop Guillain Barré syndrome.~~
2. (currently amended) A mouse model of Guillain-Barré syndrome according to claim 1, wherein Guillain-Barré syndrome is Fisher syndrome.
3. (currently amended) The mouse model of Guillain-Barré syndrome according to the mouse model in claim 1 or 2, which develops peripheral neuropathy wherein paralysis of its tail and hind legs and elevated levels of antibody titer against GQ1b occurs.
- 4-5. (canceled)
6. (currently amended) A screening method of a therapeutic agent for Guillain-Barré syndrome and/or Fisher syndrome comprising, administering wherein a test substance is administered to the mouse model of Guillain Barré syndrome according to any one of claim[[s 1 to]] 3, to

observe and observing and assessing the degree of symptoms of Guillain-Barré syndrome and/or Fisher syndrome in the mouse model of the syndrome.

7. (currently amended) A screening method of a therapeutic agent for Guillain-Barré syndrome and/or Fisher syndrome comprising, administering wherein a test substance is administered to the mouse model of Guillain Barré syndrome according to any one of claim[[s 1 to]] 3, to measure and measuring and assessing the level of anti-GQ1b antibody appearance present in the mouse model of the syndrome.

8. (currently amended) A therapeutic agent that can be obtained by the screening method of a therapeutic agent for Guillain-Barré syndrome and/or Fisher syndrome according to claim 6 [[or 7]].

9. (new) A therapeutic agent obtained by the screening method of a therapeutic agent for Guillain-Barré syndrome and/or Fisher syndrome according to claim 7.